高危复杂PCI患者抗血小板治疗的时间调节:TAILORED-CHIP随机临床试验
TAILORED-CHIP试验将2018例高危复杂PCI患者随机分为定制抗血小板策略组(早期强化:低剂量替格瑞洛60mg每日两次+阿司匹林<6个月;后期降阶:氯吡格雷单药>6个月)或双联抗血小板治疗组(氯吡格雷+阿司匹林12个月)。
要点
- 高危复杂PCI患者中,定制抗血小板策略未显著降低12个月净不良事件。
- 定制组临床相关出血发生率7.2%,高于双联组的4.8%(差异2.45个百分点,95%CI 0.37-4.53)。
- 主要缺血事件两组相似,但定制策略未带来获益。
核心结论
- 在高危复杂PCI患者中,与双联抗血小板治疗相比,早期强化后晚期降阶的定制抗血小板策略未降低12个月主要净不良事件发生率。
研究设计与样本
- 多中心随机临床试验,纳入2018例具有高危解剖或临床特征并接受复杂PCI的患者。
- 随机分为定制抗血小板策略组(早期低剂量替格瑞洛60mg每日两次+阿司匹林<6个月,后期氯吡格雷单药>6个月)或双联抗血小板治疗组(氯吡格雷+阿司匹林12个月)。
- 主要终点为12个月全因死亡、心肌梗死、卒中、支架血栓、计划外紧急血运重建和临床相关出血(BARC 2、3或5型)的复合终点。
主要发现
- 主要缺血事件发生率两组相似。
- 12个月临床相关出血发生率定制组7.2%,双联组4.8%(差异2.45个百分点,95%CI 0.37-4.53)。
临床怎么用
- 对于高危复杂PCI患者,采用早期强化后晚期降阶的定制抗血小板策略并未减少净不良事件,且出血风险数值上更高,需谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Limited data exist on optimal antiplatelet strategies for high-risk patients undergoing complex percutaneous coronary intervention (PCI). This study aimed to investigate the efficacy and safety of tailored antiplatelet treatment with temporal modulation of the intensity of platelet inhibition in patients undergoing complex high-risk PCI. METHODS: We randomly assigned 2018 patients with high-risk anatomical or clinical characteristics undergoing complex PCI to a tailored antiplatelet strategy with early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months) and late de-escalation (clopidogrel monotherapy >6 months) or dual antiplatelet therapy (clopidogrel plus aspirin for 12 months). The primary outcome was a composite of death from any cause, myocardial infarction, stroke, stent thrombosis, unplanned urgent revascularization, and clinically relevant bleeding (Bleeding Academic Research Consortium Type 2, 3, or 5) at 12 months. RESULTS: The mean age was 64.0 years, 22.6% had left main PCI, 19.5% had complex bifurcation PCI, 84.1% had diffuse long lesions, 93.7% had multivessel PCI, and 36.7% had medically treated diabetes. At 12 months, a primary outcome event occurred in 105 patients (10.5%) assigned to tailored antiplatelet therapy and in 89 patients (8.8%) assigned to dual antiplatelet therapy [hazard ratio, 1.19; 95% confidence interval (CI), 0.90-1.58; P = .21]. The incidence of major ischaemic events appeared to be similar in both groups. The incidence of clinically relevant bleeding at 12 months was 7.2% in the tailored-therapy group and 4.8% in the dual-therapy group (difference, 2.45% points; 95% CI, 0.37-4.53). CONCLUSIONS: Among high-risk patients undergoing complex PCI, tailored antiplatelet strategy with early escalation and late de-escalation, as compared with dual antiplatelet therapy, did not decrease the incidence of primary net adverse events at 12 months. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT03465644.
引用
- Kang DY, Wee SB, Ahn JM, et al. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Eur Heart J. 2026. PMID: 40886179. doi:10.1093/eurheartj/ehaf652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。